Slide 1: Investor Presentation August 2026
Investor Presentation August 2026 Exhibit 99.2
Slide 2: Legal Disclaimers
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even
Slide 3: A Leader in Sustained Release Drug Delivery for Retinal Disease
A Leader in Sustained Release Drug Delivery for Retinal Disease 1.Unaudited estimate as of June 30, 2026. AMD, age-related macular degeneration; DME, diabetic macular edema DURAVYUTM has been conditionally accepted by the FDA as the proprietary name for DURAVYU. DURAVYU is an investigational product
Slide 4: DURAVYU in Phase 3 Trials For the Two Largest Retinal Disease Markets
DURAVYU™ in Phase 3 Trials For the Two Largest Retinal Disease Markets AMD, wet age-related macular degeneration; DME, diabetic macular edema; FDA, Food and Drug Administration Durasert E™ Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Anticipated Milestone DURAVYU™ (vorolanib intrav
Slide 5: Products Addressing Unmet Needs Capture Meaningful Share in $15B Anti-VEGF Market
Products Addressing Unmet Needs in Retinal Disease Capture Meaningful Market Share in $15B Anti-VEGF Market 1. Publicly reported sales; 2. Lucentis package insert; 3. Khanani et. al, The Real-World Efficacy and Safety of Faricimab in Neovascular Age Related Macular Degeneration: TRUCKEE Study – 2 Ye
Slide 6: Longer Duration and New MOA are Key Unmet Needs in Retinal Disease
Longer Duration and New MOA are Key Unmet Needs in the Current Retinal Disease Treatment Paradigm Insert not drawn to scale and is enlarged for illustrative purposes. The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection. MOA, mechanism of action; IL-6, i
Slide 7: Vorolanib Features a Multi-MOA, Addressing Vascular Leakage and Inflammation
Vorolanib Features a Multi-MOA, Potentially Addressing Both Vascular Leakage and Inflammation Data on file. Bakri SJ, et al. PLoS One. 2024;19(6):e0304782. IL-6 (R), interleukin 6 (receptor); JAK, janus kinase; MOA, mechanism of action; PDGF(R), platelet-derived growth factor (receptor); PLGF, place
Slide 8: Durasert E: A Next Generation in Sustained-Release Intravitreal Drug Delivery
Durasert E™: A Next Generation in Sustained-Release Intravitreal Drug Delivery Vitrasert® (ganciclovir IVT)1,a Retisert® (fluocinolone acetonide)2 ILUVIEN® (fluocinolone acetonide)3 YUTIQ® (fluocinolone acetonide)4 DURAVYU™ (vorolanib IVT insert; a/k/a EYP-1901) APPROVED NONERODIBLE | Durasert® INVE
Slide 9: DURAVYU: Potential Best-in-Class TKI for Retinal Disease
DURAVYU™: Potential Best-in-Class TKI for Retinal Disease The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection. a. Data from preclinical studies. Following a single DURAVYU 900 µg dose in Dutch-Belted rabbits, vorolanib reached concentrations exceeding I
Slide 10: DURAVYU Has Demonstrated a Consistent Favorable Safety Profile Across Clinical Trials
DURAVYU Has Demonstrated a Consistent Favorable Safety Profile Across Multiple Clinical Trials * Based on a single dose of DURAVYU 1. EyePoint. Press release May 14, 2026: EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence A
Slide 11: DURAVYU for Wet AMD
DURAVYU for Wet AMD Phase 3 program designed to transform the treatment paradigm through durable disease control and a new multi-moa
Slide 12: DAVIO 2 Results: All Primary and Secondary Endpoints Were Achieved
DURAVYU Phase 3 Trials in Wet AMD Supported by DAVIO 2 Results: All Primary and Secondary Endpoints Were Achieved DAVIO 2 Endpoints in Wet AMD* 2mg 3mg R Primary: Statistically significant non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Change in BCVA vs. baselin
Slide 13: LUGANO and LUCIA: Pivotal Phase 3 Wet AMD Program
LUGANO and LUCIA: Clinically Rigorous Pivotal Phase 3 Wet AMD Program Following Established Non-Inferiority Regulatory Path & Three consecutive positive DSMC reviews with no protocol changes required Over 900 patients enrolled Topline data expected for LUGANO in August 2026; LUCIA in Q4 2026 Key Ele
Slide 14: Pivotal Trial Design Follows Established Non-Inferior Regulatory Pathway
Pivotal Trial Design Follows Established Non-Inferior Regulatory Pathway DURAVYU dosing consists of 2 inserts delivered in a single injection. AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; D, day; W, week; EOS, end-of-study; q6M, every 6 months; q8W, every 8 weeks; R, ra
Slide 15: Key Refinements from Phase 2 Drive Confidence in Phase 3 Wet AMD Program
Key Refinements from Phase 2 Trial Drives Confidence in Phase 3 Wet AMD Program DAVIO 2 LUGANO / LUCIA Patient Population 100% previously treated 75% treatment naïve, 25% previously treated Supplement Criteria 5 separate and independent criteria, including Investigator discretion 2 supplement criter
Slide 16: Retrospective Subgroup Analysis of DAVIO 2 Patients
DURAVYU in Wet AMD: Retrospective Subgroup Analysis of DAVIO 2 Patients Reflects Supportive Outcomes in BCVA and OCT This retrospective and unplanned subgroup analysis is not predictive of the outcome of the Phase 3 program. DURAVYU is not approved in any country and its safety and efficacy have not
Slide 17: DURAVYU for DME
DURAVYU for DME Phase 3 program underway in second largest retinal disease market
Slide 18: COMO and CAPRI: Phase 3 DME Program
COMO and CAPRI: Phase 3 DME Program Designed to Enable Potential Global Regulatory and Commercial Success First patients dosed in both trials in February 2026 Full enrollment in July 2026 Topline data expected in 4Q 2027 Key Elements of Phase 3 Trial Design: Informed by positive Phase 2 VERONA trial
Slide 19: Phase 3 Pivotal Trials in DME: Non-Inferiority vs On-Label Aflibercept
Phase 3 Pivotal Trials in DME: Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control D1 W4 W8 W12 W161 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W60 to W68 W72 W76 to W84 W88 EOS Primary endpoint Blend W52 & W56 DURAVYU 2.7 mg Aflibercept 2 mg q8W DURAVYU dosing DURAVYU dosin
Slide 20: Phase 2 VERONA: Single DURAVYU Treatment Showed Vision and Anatomical Improvement
Phase 2 VERONA: Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Vision and Anatomical Improvement as Early as Week 4 BCVA, best-corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study;. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data
Slide 21: DURAVYU in Supplement-Free Eyes Achieved Similar BCVA as Anti-VEGF + Anti-IL-6
DURAVYU 2.7mg in Supplement-Free Eyes Achieved Similar BCVA as Anti-VEGF + Anti-IL-6 Dosed Monthly* BCVA: VERONA DME results superimposed on BARDENAS Phase 2 Trial of anti-IL6 (vamikibart) * Cross-trial comparisons are presented for informational purposes only. These studies were conducted independe
Slide 22: Dose-Dependent Reduction in Macular Leakage Area with Single DURAVYU Injection
Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection in DME Illustrative patient case; not representative of all observed cases or predicative of treatment outcomes 1. Change from baseline in vascular leakage (mm2) in the macula and in the total retinal area. Full analysi
Slide 23: Continued Drying with Improved BCVA After a Single DURAVYU Dose
Continued Drying at Week 24 with Improved BCVA After a Single DURAVYU 2.7mg Dose and No Supplementation Illustrative patient case; not representative of all observed cases or predicative of treatment outcomes. BCVA, best-corrected visual acuity; CST, central subfield thickness; D, day; VA, visual ac
Slide 24: Commercial Manufacturing Facility Built to Support DURAVYU Through Potential NDA Approval
Commercial Manufacturing Facility Built to Support DURAVYU Through Potential NDA Approval and U.S. Commercial Launch NDA, New Drug Application; FDA, Food and Drug Administration; EMA, European Medicines Agency USA based in Northbridge, MA Built to US FDA and EU EMA standards DURAVYU registration bat
Slide 25: DURAVYU: Potential to be First To Market and Best in Class TKI
DURAVYU™: Potential to be the First To Market and Best in Class TKI in Largest Retinal Disease Markets Vorolanib, a multi-MOA TKI with potential every 6-month dosing Extensive Phase 1 and 2 efficacy data in wet AMD and DME Favorable safety and tolerability with no drug-related safety concerns across
Slide 26: Investor Presentation August 2026
Investor Presentation August 2026